Welcome to our dedicated page for ORASURE TECHNOLOGIES SEC filings (Ticker: OSUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ORASURE TECHNOLOGIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ORASURE TECHNOLOGIES's regulatory disclosures and financial reporting.
OraSure Technologies reported second quarter 2026 net revenues of $30.6 million, up 10% sequentially but down 2% from a year earlier, with core revenues also at $30.6 million and roughly flat year over year. Diagnostics revenue rose 1% to $19.4 million, while Sample Management Solutions revenue was steady at $9.9 million.
GAAP gross margin improved to 43.5% from 42.1%. A $22.6 million reduction of acquisition-related contingent consideration drove GAAP operating income of $5.4 million and GAAP net income of $6.2 million, or $0.09 per diluted share, although non-GAAP results showed a net loss of $13.8 million and non-GAAP diluted loss per share of $0.20.
Cash and cash equivalents totaled $161 million as of June 30 2026. The company has repurchased about $22 million, or 7.7 million shares, of common stock under a $40 million authorization, exceeding 10% of shares outstanding. Recent milestones include FDA clearance of the Colli-Pee™•Dx urine collection kit, FDA Emergency Use Authorization for the OraQuick™ Ebola 2.0 Rapid Antigen Test, and Q3 2026 revenue guidance of $29.5–$32.5 million.
OraSure Technologies Inc. has a significant shareholder disclosure from Private Management Group, Inc. The investment adviser reports beneficial ownership of 3,797,682 shares of OraSure common stock, representing 5.5% of the class as of June 30, 2026.
Private Management Group has sole voting and sole dispositive power over all 3,797,682 shares and no shared voting or dispositive power. The shares are held across various separately managed accounts for which the firm acts as investment adviser, and those account holders are entitled to receive dividends and sale proceeds.
OraSure Technologies director Steven Kyle Boyd received a stock-based fee grant. He was awarded 3,666 shares of common stock at a reference price of $4.4325 per share as a grant or award acquisition.
The footnote explains these are restricted shares granted under the OraSure Technologies, Inc. Stock Award Plan, with immediate vesting on the grant date. The shares were issued in lieu of cash director fees, at Boyd's election under the company's Director Compensation Policy. After this grant, he directly owns 163,234 common shares.
OraSure Technologies, Inc. reported that the U.S. Food and Drug Administration granted clearance for its Colli-Pee™•Dx Urine Collection Kit, developed by subsidiary DNA Genotek Inc., for use with several Roche Molecular Systems tests for common sexually transmitted infections.
The kit is cleared for use with Roche tests for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium on Roche’s cobas® 5800, 6800, and 8800 molecular diagnostic systems. The FDA-cleared kit supports at-home self-collection of first-void urine, enabling more convenient sample collection for both male and female patients.
McMahon Robert W. reported acquisition or exercise transactions in this Form 4 filing.
OraSure Technologies director Robert W. McMahon received an equity grant as board compensation. He was awarded 46,106 shares of common stock as restricted stock, at no cash cost, increasing his direct holdings to 123,137 shares.
The restricted shares were granted under the OraSure Technologies, Inc. Stock Award Plan and will vest in full on the earlier of June 3, 2027 or immediately before the company’s 2027 Annual Meeting of Stockholders. Vesting will stop, and unvested shares will not vest, if he voluntarily leaves the Board of Directors before that time.
Gagliano Nancy J reported acquisition or exercise transactions in this Form 4 filing.
OraSure Technologies director Nancy J. Gagliano received a grant of 46,106 shares of common stock as a stock award. The grant consists of restricted shares under the OraSure Technologies, Inc. Stock Award Plan, provided as compensation rather than an open-market purchase.
The restricted shares will vest in full on the earlier of June 3, 2027, or immediately before the start of the company’s 2027 annual stockholders meeting, as long as she continues serving on the board. Vesting will stop immediately if she voluntarily leaves the board, so the award is tied to ongoing service. Following this grant, she holds 185,055 shares directly.
Marmora Lelio reported acquisition or exercise transactions in this Form 4 filing.
OraSure Technologies director Lelio Marmora received a grant of 46,106 shares of Common Stock as a stock award, not through an open-market purchase. The shares were granted at no cash cost as part of the OraSure Technologies, Inc. Stock Award Plan.
The restricted shares will vest in full on the earlier of June 3, 2027, or immediately before the start of the company’s 2027 Annual Meeting of Stockholders, provided Marmora continues to serve on the board. Vesting stops immediately if he voluntarily leaves the board. After this grant, he directly holds 148,460 shares.
Kenny John P. reported acquisition or exercise transactions in this Form 4 filing.
OraSure Technologies director John P. Kenny received a grant of 46,106 shares of Common Stock as a stock award. The grant was made at a price of $0.00 per share, increasing his direct holdings to 209,714 shares after the transaction.
According to the award terms, these restricted shares will vest in full on the earlier of June 3, 2027 or immediately before the start of the company’s 2027 Annual Meeting of Stockholders. Vesting will stop immediately if he voluntarily leaves the Board before that time.
Bertrand John D. reported acquisition or exercise transactions in this Form 4 filing.
OraSure Technologies director John D. Bertrand received a grant of 46,106 shares of Common Stock as an equity award. The shares are restricted and were granted at no cash cost to him.
The award vests in full on the earlier of June 3, 2027 or immediately before the company’s 2027 Annual Meeting of Stockholders, provided he continues serving on the Board. Vesting stops if he voluntarily leaves the Board, meaning unvested shares would not be earned. After this grant, he directly holds 79,767 OraSure shares.
Boyd Steven Kyle reported acquisition or exercise transactions in this Form 4 filing.
OraSure Technologies director Steven Kyle Boyd received a grant of 46,106 shares of common stock as a restricted stock award. The shares were granted at no cash cost to him and are part of the OraSure Technologies, Inc. Stock Award Plan.
These restricted shares will vest in full on the earlier of June 3, 2027, or immediately before the start of the company’s 2027 Annual Meeting of Stockholders, as long as he continues to serve on the Board. If he voluntarily leaves the Board before that time, vesting stops immediately. After this grant, Boyd directly holds 159,568 OraSure shares.